U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 2131 - 2140 of 39119 results

Status:
Investigational
Source:
INN:lexofenac
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Lexofenac is an ibufenac derivative. It was developed as anti-inflammatory and analgesic agent.
Status:
Investigational
Source:
INN:suxemerid
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Suxemerid is a succinic acid derivative patented by Warner-Lambert Pharmaceutical Co. as an antihypertensive agent.
Status:
Investigational
Source:
INN:capravirine
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Capravirine (S-1153, AG1549) is a 1,2,4,5-tetrasubstituted imidazole derivative patented by pharmaceutical company Shionogi as specific inhibitors of HIV-​1 reverse transcriptase. However, safety and efficacy studies showed that Capravirine had no specific advantages over currently used NNRTIs. Consequently, clinical trials were discontinued after phase IIb.
Status:
Investigational
Source:
INN:clofenamic acid
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Clofenamic acid is a derivative of anthranilic acid, discovered by Parke-Davis. It possesses anti-inflammatory activity in the carrageenan-induced rat foot edema test.
AT-9283 was being developed by Astex Pharmaceuticals as a treatment for cancer and myelofibrosis. AT-9283 is an inhibitor of mitosis (cell division) and is the second most progressed drug candidate in the Astex portfolio of novel molecularly targeted cancer drugs. All of Astex’s current products have been discovered internally using its proprietary drug discovery approach. AT9283 is a potent inhibitor of the Aurora A and B kinases and has been shown to arrest tumour growth in a range of tumour models. Aurora kinases play a key role in mitotic checkpoint control in cell division. Both Aurora A and B are over-expressed in many human tumours and are believed to be excellent targets for anti-cancer therapy.
Status:
Investigational
Source:
INN:clinolamide [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Clinolamide (cyclohexylamine of linoleic acid) is a drug developed by a Japanese company Sumitomo Chemical Co. Ltd. Clinolamide has been found to lower serum and liver cholesterol levels and to reduce the severity of atherosclerosis in cholesterol-fed rabbits.
Status:
Investigational
Source:
JAN:CINACIGUAT [JAN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)



Cinaciguat acts specifically on oxidized/haem-free soluble guanylyl cyclase by binding to the enzyme's haem pocket and mimicking the nitric-oxide-bound haem group. It is in clinical development for the treatment of acute decompensated heart failure. Cinaciguat had been in phase II clinical trials. However, trials were terminated early because of an excess of hypotension in the cinaciguat arms and subsequent slow enrolment.
Status:
Investigational
Source:
INN:flestolol
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

FLESTOLOL is an ultra-short-acting beta-adrenergic blocking agent without any intrinsic sympathomimetic activity.
Status:
Investigational
Source:
INN:rivoglitazone
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Rivoglitazone hydrochloride (CS-011) is a thiazolidinedione-derivative peroxisome proliferator–activated receptor (PPAR)-γ agonist. It has been developed as potential treatment in type 2 diabetes mellitus and was shown to decrease plasma glucose and triglyceride levels in a dose-dependent manner in animals. Phase II and III clinical studies have assessed the efficacy and safety of rivoglitazone hydrochloride in patients with type 2 diabetes mellitus.
Status:
Investigational
Source:
INN:cefsumide
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Cefsumide is an antibiotic of the cephalosporin group patented by Fujisawa Pharmaceutical Co. Cefsumide binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.

Showing 2131 - 2140 of 39119 results